Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies

Reports of fidaxomicin treatment for patients with multiple recurrent Clostridium difficile infections ([mrCDI] ie, more than 2 CDI episodes) indicate symptomatic response to this agent, but 50% have subsequent mrCDI episodes. In an effort to improve outcomes in patients with mrCDI we used novel reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Soriano, Melinda M., Danziger, Larry H., Gerding, Dale N., Johnson, Stuart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281782/
https://www.ncbi.nlm.nih.gov/pubmed/25734139
http://dx.doi.org/10.1093/ofid/ofu069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281782/
https://www.ncbi.nlm.nih.gov/pubmed/25734139
http://dx.doi.org/10.1093/ofid/ofu069

Ejemplares similares